There was a lot of excitement when Tepezza became the first drug approved for the treatment of thyroid eye disease in January 2020. Then, COVID hit.“Sort of terrible timing with regards to that,” Richard C. Allen, MD, PhD, FACS, said. “There was a lot …
Author: Healio ophthalmology
Eylea HD extends dosing intervals in DME, wet AMD
SALT LAKE CITY — In this Healio Video Perspective from the ARVO meeting, Michael Javaheri, MD, overviews real-world data on Eylea HD in diabetic macular edema and wet age-related macular degeneration.Javaheri reported an average treatment interval of 7…
Tecnis Odyssey IOL improves vision at all ranges
LOS ANGELES — In this Healio Video Perspective from the ASCRS meeting, Brian Schwam, MD, discusses a trio of presentations investigating the Tecnis Odyssey IOL.Schwam said the Tecnis Odyssey (Johnson & Johnson Vision) is the fastest-growing presbyopia-…
Age, sex may affect retinal vasculature in glaucoma
SALT LAKE CITY — In this Healio Video Perspective from the ARVO meeting, Osamah J. Saeedi, MD, discusses a study that looked at the impact of age and sex on retinal vasculature in patients with glaucoma.According to Saeedi, an analysis of more than 88,…
Omni Edge provides ‘comprehensive’ glaucoma treatment
LOS ANGELES — In this Healio Video Perspective, Mark Papini of Sight Sciences overviews the Omni Edge Surgical System for glaucoma, which debuted at the ASCRS meeting.According to Papini, the Omni Edge’s TruSync technology enables the “safe, reproducib…
FDA accepts reproxalap new drug application for dry eye again
The FDA accepted a resubmitted new drug application for reproxalap, a first-in-class investigational topical therapy for dry eye disease, according to a press release from Aldeyra Therapeutics.The FDA, which did not approve a previous resubmission for …
Eye drop promising for vascularized pinguecula
Editor’s note: This is a developing news story. Please check back soon for updates.Cloudbreak Pharma reported positive topline results from a phase 2 clinical trial that assessed a preservative-free ophthalmic solution for the treatment of vascularized…
Q&A: CMS’ proposed physician fee schedule and other Medicare updates for physicians
CMS issued the 2026 Medicare Physician Fee Schedule, or PFS, proposed rule on July 14.It includes a 0.75% increase to the qualifying alternative payment model (APM) conversion factor — a $1.24 (3.83%) rise from the current APM conversion factor of $32….
Is systemic therapy the best option for uveitic macular edema?
SEVILLE, Spain — Treatments for uveitic macular edema, including systemic and local options, were among the topics debated at the Congress on Controversies in Ophthalmology.Macular edema develops in up to 30% of uveitic eyes and is the most prevalent f…
Oral danegaptide for diabetic retinopathy successfully completes phase 1b trial
Danegaptide, a potential oral therapy for nonproliferative diabetic retinopathy, is advancing to a phase 2 trial after showing a favorable safety profile in a phase 1b trial, according to a press release from Breye Therapeutics.The therapy could be use…
Woman presents with acute unilateral burning, blurry vision
A 64-year-old woman presented to an outside provider with 5 days of left eye “burning, itching, redness and blurry vision” and 1 day of acute “9 out of 10” left eye pain.She had a medical history of obesity, anemia, basal cell carcinoma, sinusitis, oti…
What I have learned from performing cataract surgery on fellow ophthalmologists
Over the years, like many other ophthalmologists, I have enjoyed performing tens of thousands of cataract surgeries, and I have learned so much in the process.Even now, decades after learning cataract surgery, I am still excited to push my skills furth…
Pharmaceutical sales representatives: Good ones become teammates
Boy, I know that there are some really terrible jobs in the extended health care universe, but it sure seems like one of them has to be the pharmaceutical sales representative.You know, the sales reps who are customer-facing foot soldiers and spend the…
VIDEO: ‘New paradigm’ emerging in neovascular AMD treatment
LAS VEGAS — In this video, Baruch D. Kuppermann, MD, PhD, of University of California, Irvine, discusses presentations on neovascular age-related macular degeneration at Clinical Trials at the Summit.“In the future, with these drug delivery products, […
WIO Summer Symposium encourages attendees to ‘learn, laugh, lift’
The Women in Ophthalmology Summer Symposium returns next month with more than 22 hours of CME, anchored by a scientific program designed to foster community, encourage collaboration and remind attendees not to forget the joy in the journey.Janet Leath …
Harrow to obtain US commercial rights to Byooviz, Opuviz
Harrow has entered into an agreement with Samsung Bioepis for the U.S. commercial rights to two ophthalmology biosimilars, according to a press release.The agreement includes Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab, G…
FDA fast tracks intravitreal gene therapy for geographic atrophy
Editor’s note: This is a developing news story. Please check back soon for updates.The FDA granted fast track designation to SAR446597, an intravitreal gene therapy for the treatment of geographic atrophy due to age-related macular degeneration, accord…
Cequa reduces dry eye signs, symptoms in 7 days
LOS ANGELES — Higher-order aberrations and other signs and symptoms of dry eye were significantly improved after as few as 7 days of treatment with Cequa, according to a study presented here.The results suggest that Cequa (cyclosporine ophthalmic solut…
Pinhole pupilloplasty vs. pinhole IOL
Click here to read the Cover Story, ” Pinhole pupilloplasty: A simple, effective alternative to corneal transplantation . “In recent years, the issue of correcting higher-order aberrations has become increasingly relevant, particularly in patients who …
Astaxanthin may decrease chronic, acute digital eye strain symptoms in children
Daily use of astaxanthin from AstaReal reduced chronic and acute symptoms of digital eye strain in school-aged children, according to a study published in Advances in Therapy.“The impact of computer vision syndrome and eye strain in children is not ful…